18 results with keyword: 'prevalence brca mutations young triple negative breast cancer'
The decision to offer genetic testing to a breast cancer patient is usually based on her family history, but in the absence of a family history of cancer, some women may qualify
N/A
In studies with selected patients referred for BRCA genetic testing, the frequency of TNBC has been reported to be 57% in BRCA1 mutation carriers and 23% in BRCA2 mutation
N/A
In unselected triple negative breast cancers, around 19% mutations were reported in the BRCA1/2 genes including also scattered somatic mutations (15% in BRCA and 3.9% in BRCA2
N/A
A Fortran IV computer program has been written which gives a means of calibrating the quasi-elastic peaks obtained from the time-of-flight data of the ISPRA-1 Double
N/A
Pathological complete response (pCR) rates after carboplatin- containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple-negative breast
N/A
BRCA1 gene [19, 20] and evaluation limited to small- range mutations [16, 21, 22]. In order to determine the utility of genetic testing for BRCA1 and BRCA2 germ- line mutations
N/A
TNBC: triple negative breast cancer; TNBCs: triple negative breast cancer patients; NAC: neoadjuvant chemotherapy; PD: progressive disease; TILs: tumor
N/A
triple-negative breast cancers need different types of treatments because they are estrogen receptor-negative, progesterone receptor-negative and HER2 negative.. Med- icines
N/A
Even some women who have had breast cancer do not understand the differences between triple-negative breast cancers and breast cancers that are hormone receptor-positive or
N/A
Triple Negative Breast Cancer: Incidence Rates; Phenotype, Triple Negative Breast Cancer: Incidence Rates; Phenotype, Demographic, and Treatment Characteristics; Model for Risk
N/A
Even some people who have had breast cancer do not understand the differences between triple- negative breast cancers and breast cancers that are hormone receptor-positive
N/A
placebo-controlled, phase 2b study evaluating the effi cacy and safety of sorafenib in combination with paclitaxel as a fi rst line therapy in patients with locally recurrent
N/A
Childless participants 18 to 30 years old belonging to hereditary breast/ovarian cancer (HBOC) families and tested for BRCA mutations (positive or negative), but without
N/A
TNT: a randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced triple negative or BRCA 1/2 breast
N/A
METHODS: African American and white American women with invasive cancer diagnosed at the Henry Ford Health System comprised the primary study population, and Ghanaian patients
N/A
While some teacher education programs had reasonable enrolment of Indigenous students commensurate with the percentage of Indigenous people in their state, the scans
N/A
Key Words: androgen receptor, breast cancer, breast cancer molecular subtypes, cancer treatment, immune checkpoint blockade, targeted therapy, triple-negative
N/A